» Articles » PMID: 29145311

Pulmonary Hypertension As a Manifestation of Mitochondrial Disease: A Case Report and Review of the Literature

Overview
Specialty General Medicine
Date 2017 Nov 18
PMID 29145311
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mitochondrial diseases are a group of multisystem heterogeneous diseases caused by pathologic dysfunction of the mitochondrial respiratory chain. A wide range of clinical expression has been described. However, pulmonary hypertension has rarely been described in association with mitochondrial disease until the past decade, and there is no currently recognized treatment for the pulmonary hypertension complicated with mitochondrial disorder.

Patient Concerns: We reported the case of a 15-year-old boy who presented with shortness of breath and exercise limitation after a cold, and the diagnosis of pulmonary hypertension was confirmed by right heart catheter. Other examinations, such as blood tests, high- resolution chest computed tomography scan, and pulmonary function test, excluded other associated diseases as causes of pulmonary hypertension.

Diagnoses And Outcomes: The initial diagnosis was idiopathic pulmonary arterial hypertension and an injection of vasodilator (Treprostinil) was given. However, the dyspnea and fatigue subsequently got worsened. Tracing back his family history, together with the electromyography, nerve conduction studies, and the result of muscle biopsy, mitochondrial disease was confirmed. After treatment with vitamin E, vitamin B2, ATP, and coenzyme Q10, the patient's condition improved.

Conclusion: Pulmonary hypertension should be considered as another potential manifestation of mitochondrial disease. Both mechanism and treatment for pulmonary hypertension complicated with mitochondrial disease are unclear. Further study is necessary.

Citing Articles

Important Functions and Molecular Mechanisms of Mitochondrial Redox Signaling in Pulmonary Hypertension.

Reyes-Garcia J, Carbajal-Garcia A, Di Mise A, Zheng Y, Wang X, Wang Y Antioxidants (Basel). 2022; 11(3).

PMID: 35326123 PMC: 8944689. DOI: 10.3390/antiox11030473.


Exercise Testing, Physical Training and Fatigue in Patients with Mitochondrial Myopathy Related to mtDNA Mutations.

Jeppesen T, Madsen K, Poulsen N, Lokken N, Vissing J J Clin Med. 2021; 10(8).

PMID: 33924201 PMC: 8074604. DOI: 10.3390/jcm10081796.


Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.

Suliman H, Nozik-Grayck E Antioxid Redox Signal. 2019; 31(12):843-857.

PMID: 30604624 PMC: 6751393. DOI: 10.1089/ars.2018.7705.


Recurrent inhibition of mitochondrial complex III induces chronic pulmonary vasoconstriction and glycolytic switch in the rat lung.

Rafikova O, Srivastava A, Desai A, Rafikov R, Tofovic S Respir Res. 2018; 19(1):69.

PMID: 29685148 PMC: 5914012. DOI: 10.1186/s12931-018-0776-1.

References
1.
Chinnery P, Turnbull D . Epidemiology and treatment of mitochondrial disorders. Am J Med Genet. 2001; 106(1):94-101. DOI: 10.1002/ajmg.1426. View

2.
Clark J, Reddy S, Zheng K, Betensky R, Simon D . Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease. BMC Med Genet. 2011; 12:69. PMC: 3112073. DOI: 10.1186/1471-2350-12-69. View

3.
Dahl H, Thorburn D . Mitochondrial diseases: beyond the magic circle. Am J Med Genet. 2001; 106(1):1-3. DOI: 10.1002/ajmg.1427. View

4.
Waypa G, Schumacker P . Role for mitochondrial reactive oxygen species in hypoxic pulmonary vasoconstriction. Novartis Found Symp. 2006; 272:176-92. View

5.
Lembke A, Gomez R, Tenakoon L, Keller J, Cohen G, Williams G . The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology. 2012; 38(1):115-21. PMC: 3633490. DOI: 10.1016/j.psyneuen.2012.05.006. View